万泰生物: 万泰生物关于公司九价人乳头瘤病毒疫苗（大肠埃希菌）首次获得批签发证明的公告

Core Viewpoint - Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. has announced that its subsidiary, Xiamen Wantai Canghai Biological Technology Co., Ltd., has received the batch release certificate for its nine-valent human papillomavirus (HPV) vaccine, marking its official market launch [1]. Group 1: Product Information - Product Name: Nine-valent human papillomavirus vaccine (E. coli) [1] - Approval Conclusion: Issued [1] - Production Company: Xiamen Wantai Canghai Biological Technology Co., Ltd. [1] Group 2: Impact on the Company - The approval of the nine-valent HPV vaccine will enhance the company's product portfolio, creating new revenue and profit growth points [1]. - The introduction of the nine-valent HPV vaccine, alongside the existing bivalent HPV vaccine, will establish a differentiated and competitive product matrix to meet diverse market needs [1]. - This development is expected to strengthen the company's profitability and market competitiveness, reinforcing its market position [1].